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SUMMARY
Several other journal supplements have documented progress made in the control of schistosomiasis in Egypt, China and
Brazil, however, with more than 97% of the schistosome infections now estimated to occur in Africa, the relevance of
this special issue in Parasitology cannot be overemphasized. In total, 18 articles are presented, inclusive of a lead-editorial
from the WHO highlighting a seminal resolution at the 54th World Health Assembly in 2001 that advocated de-worming.
Facilitated by a US$ 30 million grant from the Bill and Melinda Gates Foundation in 2002, the Schistosomiasis Control
Initiative subsequently fostered implementation of large-scale schistosomiasis (and soil-transmitted helminthiasis) control
programmes in six selected African countries. From 2005, CONTRAST, a European union-funded consortium, was
formed to conduct multi-disciplinary research pertaining to optimisation of schistosomiasis control. Progress made in
schistosomiasis control across sub-Saharan Africa since the turn of the new millennium is reviewed, shedding light on the
latest ﬁndings stemming from clinical, epidemiological, molecular and social sciences research, inclusive of public health
interventions with monitoring and evaluation activities. New opportunities for integrating the control of schistosomiasis
and other so-called neglected tropical diseases are highlighted, but more importantly, several opportune questions that
arise from it frame the remaining challenges ahead for an enduring solution.
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INTRODUCTION
For centuries, three countries have been intimately
linked with human schistosomiasis: Egypt, China
and Brazil. Indeed, the associations go back even
further (circa 1900 BC) as evidenced by Egyptian
hieroglyphs on papyri and in paintings that might
depict blood in urine (endemic haematuria), likely
caused by urinary schistosomiasis (Jordan and
Webbe, 1969; Jordan, 2000). Firm proof of the oc-
currence of urinary schistosomiasis in ancient Egypt
was obtained by the demonstration of calciﬁed
Schistosoma haematobium eggs within the kidneys
of two Egyptian mummies dating back over three
millennia ago (Adamson, 1976). Most importantly,
perhaps, was the discovery in 1851 of adult schisto-
some worms within a human at autopsy in Cairo by
the German physician Theodor Bilharz, which gave
rise to a disease forever associated with his name,
bilharzia (Davis, 2009). In China, calciﬁed S. japo-
nicum eggs were demonstrated in two exhumed
corpses dating backmore than 2000 years (Zhou et al.
2005), with the ﬁrst parasitologically-conﬁrmed case
of S. japonicum described by the American physician
Oliver T. Logan in 1905 (Utzinger et al. 2005). In
Brazil, the ﬁrst scientiﬁc work pertaining to S. man-
soniwas published in 1908 by the Brazilian physician
Piraja´ da Silva (Katz, 2008).
It is therefore not surprising that both the public
health signiﬁcance and the socio-economic import-
ance of schistosomiasis have been recognized in
Egypt, China and Brazil a long time ago, and that
huge eﬀorts have been made to control this chronic
and debilitating disease. Indeed, a key feature ex-
plaining the successes of the national schistosmiasis
control programmes of the aforementioned countries
has been better recognition of the public health
burden and fostering the necessary political will
and leadership for implementing and sustaining
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large-scale interventions (Engels et al. 2002; Wang,
Utzinger and Zhou, 2008). Reporting on these
achievements, several special issues have been pub-
lished which provide comprehensive summaries of
the epidemiology and control of schistosomiasis in
Egpyt, China and Brazil. In 2000, the American
Journal of Tropical Medicine and Hygienemarked the
start with a supplement reporting the origins, evol-
ution and main ﬁndings of large-scale epidemiolo-
gical surveys including more than 89000 individuals
from 251 rural communities in nine governorates
in Egypt (El-Khoby et al. 2000a, b). This project
was implemented from 1990 to 1994, while schisto-
somiasis control eﬀorts were already in place and
continued thereafter; most notably over 50 million
praziquantel treatment courses were administered in
Egypt between 1988 and 2001 (Fenwick et al. 2003).
A special issue of Acta Tropica, published in 2005,
commemorated the 100-year anniversary of the ﬁrst
description of S. japonicum, and highlighted prog-
ress made in the control of schistosomiasis in China.
While there were an estimated 11.6 million people
infected with S. japonicum in the mid-1950s, this
number was reduced to below a million, half a cen-
tury later (Utzinger et al. 2005; Zhou et al. 2005).
During the 10-year World Bank Loan Project, im-
plemented in the 1990s, praziquantel-based mor-
bidity control was a key pillar of the national control
programme with more than 50 million praziquantel
treatment courses administered (Chen, 2005).
Finally, in 2008, Acta Tropica published another
special issue, focusing on schistosomiasis research in
Brazil, which coincided with the ﬁrst description of
S. mansoni in this country a century ago. The unique
contributions of Brazilian clinicians, molecular
biologists, epidemiologists and social scientists to
further our understanding of the epidemiology
and control of schistosomiasis were highlighted
(Bergquist, 2008). From a public health point of
view, the large-scale administration of the anti-
schistosomal drug oxamniquine in the national
schistosomiasis control programme of Brazil is of
particular mention; more than 12 million treatment
courses were administered before gradually replacing
oxamniquine with praziquantel (Katz and Coelho,
2008).
In this special issue of Parasitology, the control of
schistosomiasis in sub-Saharan Africa is featured.
Justiﬁcation for such a special issue derived from the
following grounds:
$ recognizing the public health importance and
sheer magnitude of schistosomiasis on this con-
tinent (WHO, 2002) ;
$ realizing the growing evidence that the risk of
schistosomiasis has increased due to water re-
sources development and management in the
absence of comprehensive mitigation measures
(Steinmann et al. 2006) ;
$ growing international interest and advocacy and
changing funding landscape with new oppor-
tunities to conquer schistosomiasis and other so-
called neglected tropical diseases (Fenwick, 2006;
Hotez et al. 2007); and
$ issuing a note of caution that renewed eﬀorts to
control schistosomiasis and sustain interventions
are not allowed to falter (Utzinger et al. 2003).
The papers in this special issue summarize scien-
tiﬁc advances and progress made in the control of
schistosomiasis in sub-Saharan Africa since the turn
of the new millennium, highlighting current and
future opportunities to optimize schistosomiasis con-
trol and transmission surveillance. Also discussed
are the scope and limits for integrating the control
of schistosomiasis with other neglected tropical
diseases. From these new opportunities a host of
opportune questions arise and several remaining
challenges are identiﬁed. The special issue consists
of the current overview along with 18 contributions,
about half review-style pieces complemented with
original research and an editorial. The manuscripts
have been prepared by experts in epidemiology,
molecular parasitology, public health and social
sciences based across Africa. Most articles are co-
authored with colleagues from Africa and Europe,
demonstrating the existing and productive research
partnerships between universities, Ministries of
Health (MoH) and non-governmental organizations
(NGOs) in the South and partner institutions in the
North and international organizations, most notably
the World Health Organization (WHO).
SCHISTOSOMIASIS IN SUB-SAHARAN AFRICA
In the summer of ‘69
Exactly 40 years have elapsed since the publication
of Human Schistosomiasis by Peter Jordan and
Gerald Webbe; a seminal monograph, which care-
fully outlined all the then known ingredients for
control of schistosomiasis (Jordan and Webbe,
1969). At a time when the world’s attention was
captured by the lunar landscape, a global optimism
grew that with the right technology and political
commitment almost anything was possible – a man
could even walk on the Moon – and to share and
communicate this precise moment in time, the
peoples of the Earth were brought together by tele-
vision on 20 July 1969 to witness the Apollo
11 landing on the Moon, broadcast to at least 600
million people around the globe although only a
privileged few witnessed this event from sub-
Saharan Africa. Indeed, the moment saw the fruition
of former US president John F. Kennedy’s vision,
aired in the early 1960s, to safely land a man on the
Moon and to bring him back to Earth before the end
of the decade, but it is perhaps interesting to note at
what ﬁnancial cost the 13-year Apollo programme
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incurred. According to the National Aeronautics and
Space Administration (NASA), the estimated cost
of the Apollo programme was US$ 135 billion, as
expressed in 2005 US$ (NASA, 2009), which sets an
interesting funding barometer to measure against
present ﬁnancial contributions for control of schisto-
somiasis and other neglected tropical diseases in
Africa and elsewhere in the developing world.
Less than a month after the Moon landing, the
legendaryWoodstock Festival took place from 15–18
August 1969 in the state of New York – perhaps
deﬁning the start of a new socio-political era where
an individual’s right to drugs and medications,
either rightly or wrongly procured, was fervently
debated. Indeed equitable access to medications in
the United States of America, sub-Saharan Africa
and elsewhere continues to engender substantial
debate and in this special issue we see the arguments
further taking form.
Paradigm shift in the mid-1980s
In the 1970s and the early 1980s, transmission con-
trol, inclusive of mollusciciding and environmental
management, remained the strategy of choice to
combat schistosomiasis, although there was a grow-
ing arsenal of safe and eﬃcacious antischistosomal
drugs. The advent of praziquantel in the second half
of the 1970s (Seubert, Pohlke and Loebich, 1977),
the rapid demonstration of the excellent safety and
eﬃcacy proﬁle of praziquantel against all human
schistosome species in multi-centric trials (Davis
and Wegner, 1979), and ﬁrst experiences gained
with the large-scale administration of this drug in
Mali (Brinkmann et al. 1988) and Malawi (Wolﬀ
and Malewezi, 1989) eventually led to a paradigm
shift. Indeed, in the mid-1980s, WHO endorsed
praziquantel-based morbidity control as the new
global strategy against schistosomiasis (WHO,
1985). The ﬁrst two national schistosomiasis control
programmes carried out on the African continent
were implemented as vertical programmes. Given
the high price for praziquantel (approximately US$
1 per 600 mg tablet), major external donor support
was necessary, and it was granted by the German
Technical Cooperation, GTZ in short. The central
feature of these schistosomiasis control programmes
was praziquantel-based morbidity control, whereas
health education and improving sanitation were
complementary measures (Brinkmann et al. 1988;
Wolﬀ and Malewezi, 1989).
The May 2001 World Health Assembly
In the 1990s, the vertically-managed schistosomiasis
control programmes of Mali and Malawi were
decentralized and eﬀorts made to integrate control
activities into the MoH. However, there were rapid
recrudescences and infection prevalences soon
reached pre-intervention levels, and hence these
programmes failed to demonstrate sustainability
(Utzinger et al. 2003). Elsewhere in sub-Saharan
Africa there was a lack of interest, political will and
leadership, and ﬁnancial resources were absent or
insuﬃcient to launch new national schistosomiasis
control programmes. Access to praziquantel there-
fore remained elusive for most of the people in need,
which is partially explained by the high price of
the drug at this time, which placed it out of reach of
many ministerial budgets.
Despite these contextual determinants and econ-
omic reasons, the experiences and successes of
large-scale chemotherapy-based morbidity control
programmes in Egypt, China and Brazil (Fenwick
et al. 2003; Utzinger et al. 2005; Katz and Coelho,
2008) resulted in a sea change of schistosomiasis
control. On 22 May 2001, during the 54th World
Health Assembly (WHA) held at WHO head-
quarters in Geneva, WHA Resolution 54.19 was
endorsed. Among other issues, member states were
urged to attain ‘‘a minimum target of regular admin-
istration of chemotherapy to at least 75% and up to
100% of all school-age children at risk of morbidity
by 2010 ’’ (WHO, 2002). The importance of this
resolution was prominently featured in a policy
forum published later in 2001 in Science while, at
the same time, the danger was expressed that such
large-scale drug campaigns might jeopardize new
research as the control and subsequent elimination
of schistosomiasis might seem just around the corner
(Colley, LoVerde and Savioli, 2001). In any event,
the developments that lead to the endorsement of
WHA Resolution 54.19 and the visionary thinking
behind it are summarized in an accompanying
editorial put forth by colleagues from WHO (Savioli
et al. 2009). Most importantly, integrated control of
schistosomiasis and soil-transmitted helminthiasis
was recommended with a detailed plan of action
published in the following year; the 57-page WHO
Technical Report Series No. 912 (WHO, 2002).
Justiﬁcation for concurrently tackling morbidity due
to schistosomiasis and soil-transmitted helminthiasis
was based on the following grounds:
$ schistosomiasis and soil-transmitted helminthiasis
are co-endemic over large parts of the developing
world;
$ school-aged children are at highest risk of mor-
bidity due to schistosomiasis and soil-transmitted
helminthiasis;
$ school-aged children (those attending school and
non-attending siblings) can be reached readily
through the existing education system; and
$ there is a common intervention strategy that can
be implemented with the assistance of school
teachers, namely the large-scale administration
of safe and eﬃcacious anthelminthic drugs (prazi-
quantel against schistosomiasis and albendazole
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or mebendazole against soil-transmitted hel-
minthiasis).
Retrospectively, WHA Resolution 54.19 and the
subsequent WHO Technical Report Series No. 912
can be considered as the precursors for new pro-
posals recommending integrated control of multiple
neglected tropical diseases (Molyneux, Hotez and
Fenwick, 2005; Fenwick, 2006; Hotez et al. 2006;
Utzinger and de Savigny, 2006). The prospect and
challenges of the contemporary initiatives for in-
tegrated control of neglected tropical diseases have
been discussed (Brady, Hooper and Ottesen, 2006;
Lammie, Fenwick and Utzinger, 2006; Richards
et al. 2006; Kolaczinski et al. 2007; Parker, Allen
and Hastings, 2008; Rumunu et al. 2009).
In this current special issue, the need and future
directions for an integrated rapid mapping approach
for multiple neglected tropical diseases are outlined
(Brooker et al. 2009). Moreover, words of caution
are expressed, since the potential beneﬁts and
achievements that can be expected with preventive
chemotherapy alone might be overstated, particu-
larly after the initial stage of control which is
the reduction of morbidity (Utzinger et al. 2009). In
the long run, one must think beyond preventive
chemotherapy (Anonymous, 2004). Indeed, truly
integrated control approaches will be required,
hence complementing large-scale drug adminis-
tration with preventive measures (e.g. locally-
adapted information, education and communication
strategies, improved access to clean water and ad-
equate sanitation), alongside strengthening of health
systems and fostering intersectoral collaboration
(Utzinger et al. 2003, 2009; Holveck et al. 2007;
Singer and Castro, 2007). Recent experiences in
China, employing a comprehensive intervention
package to control the transmission of S. japonicum,
can stimulate national schistosomiasis control pro-
grammes elsewhere. Issuing from WHA Resolution
54.19, alongside recommendations for the frequency
of anthelminthic treatment (praziquantel against
schistosomiasis and albendazole or mebendazole
against soil-transmitted helminthiasis), according
to disease endemicity thresholds, are national and
regional treatment needs that are critically discussed
in this special issue (Utzinger et al. 2009).
The 2002 launch of the Schistosomiasis
Control Initiative
In 2002, facilitated by a generous start-up grant of
US$ 30 million from the Bill and Melinda Gates
Foundation, the Schistosomiasis Control Initiative
(SCI) was established. Clearly, SCI was the most
signiﬁcant response to the call of action put forth in
WHA Resolution 54.19. Indeed, SCI was at the root
of assisting six African countries (Burkina Faso,
Mali, Niger, Uganda, United Republic of Tanzania
and Zambia) that had been carefully selected based
upon schistosomiasis endemicity levels and the
countries ’ proposals for setting up and implement-
ing national schistosomiasis and soil-transmitted
helminthiasis control programmes. Fig. 1 shows the
estimated country-speciﬁc schistosome prevalence
data across Africa as of mid-2003, according to web-
appendix 2 from a recent review (Steinmann et al.
2006). The estimated schistosome prevalence was
above 50% in three of the SCI-supported countries
(Burkina Faso, Mali and United Republic of
Tanzania), whereas the respective prevalence esti-
mates were around 25% in the remaining three
countries (Niger, Uganda and Zambia). Were
schistosome endemicity estimates taken as the sole
criteria for country selection, Ghana, Madagascar,
Mozambique and Sierra Leone should have been
further considered. Of note are a new US$ 100 mil-
lion initiative granted through the United States
Agency for International Development (USAID),
and £ 50 million pledged support by the UK
Department for International Development and
US$ 350 millions from the US Government in 2008
(Hotez et al. 2009) which should result in stepping
up integrated control eﬀorts targeting multiple
neglected tropical diseases in the previously SCI-
supported countries (Garba et al. 2009) and other
sub-Saharan African countries where neglected
tropical diseases are still rampant.
The rationale, development and implementation,
including the annual number of praziquantel treat-
ments administered in each country, monitoring
activities and proposed exit strategies are described
in the ‘SCI-story’ featured in this special issue
(Fenwick et al. 2009). The ﬁrst treatment round
commenced in 2003 and targeted half a million
people, mainly in the pilot control programme in
Uganda. In 2005, close to 13 million doses of prazi-
quantel were administered in the six SCI-supported
countries and, by the end of 2008, a total of 45
million praziquantel treatments were administered.
The SCI-supported control programmes conﬁrmed
that in most settings it was possible to reach school-
aged children and to treat them with praziquantel
and albendazole for less than US$ 0.5 per capita
and per year. Whilst the total amount utilized for
schistosomiasis control is impressive, it is telling,
however, that the 4-year US$ 30 million start-up
funding from the Bill and Melinda Gates Foun-
dation for SCI translates to only a small fraction of
a percentage point (0.02%) when compared to the
13-year Apollo lunar mission programme.
In 2005: the CONTRAST research consortium
Concern had been expressed shortly after issuing
WHA Resolution 54.19 that large-scale preventive
chemotherapy-based control programmes against
schistosomiasis and other helminthic diseases might
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lower enthusiasm, ﬁnancial commitment and general
interest for basic and operational research (Colley
et al. 2001). However, an important lesson learnt
from the schistosomiasis control programmes in
Egypt, China and Brazil was that an integral re-
search component would sustain control interven-
tions and facilitate future progress as the challenge of
control will change from morbidity control to trans-
mission containment and ultimately elimination
(Utzinger et al. 2005; Bergquist, 2008). Against this
background, a multidisciplinary alliance was formed
in 2005 in Zanzibar with the goal to optimize
schistosomiasis control and transmission surveil-
lance across sub-Saharan Africa. The project was
funded by the European Union with a 4-year grant
of E 2.9 million and is known under the acronym
CONTRAST (http://www.eu-contrast.eu/) and a
key feature of the consortium was the strengthening
of institutional partnerships through establishment
of an enduring infrastructure for research with
development of ﬁve specialist research nodes across
Africa to foster cross-country research. The research
nodes can be summarized as follows:
$ a snail-parasite laboratory in Cameroon;
$ a molecular DNA laboratory in Uganda;
$ a biological reference collection centre in Kenya;
$ a demographic and socio-economic centre in the
United Republic of Tanzania; and
$ a remote sensing and spatial epidemiology lab-
oratory in Zambia.
Importantly, each research node has been twinned
with a mutually supporting European partner insti-
tution in order to pair similar sets of interest and
skill-bases to strengthen and further enhance re-
search partnerships over a longer-term perspective.
This special issue and a number of the preceding
publications document fruition of the specialist
research node structure facilitated through the
CONTRAST programme. Regarding molecular
research, a DNA barcoding approach has been em-
ployed for the identiﬁcation and classiﬁcation of
Bulinus spp., the intermediate host snail of S. hae-
matobium (Kane et al. 2008), and revealed consider-
able genetic diversity both in schistosomes and its
intermediate host snails in Uganda (Rollinson et al.
2009; Stothard et al. 2009). Regarding demographic
and socio-economic investigations, the literature
has been reviewed and highlights the role of the
social sciences to further our understanding of
the epidemiology and control of schistosomiasis in
Africa (Aagaard-Hansen, Mwanga and Bruun,
2009). Finally, with regard to remote sensing and
Fig. 1. Country-speciﬁc prevalence estimates for schistosomiasis across Africa as of mid-2003 (data obtained from
webappendix 2 from Steinmann et al. 2006).
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spatial epidemiology, CONTRAST is in the process
of developing an open-access georeferenced database
on parasite and snail surveys carried out in Africa
(Simoonga et al. 2009; Stensgaard et al. 2009) and
uses advanced Bayesian geospatial models to map
and predict the risk of schistosomiasis prevalence
and infection intensity data (Vounatsou et al. 2009).
The 2009 developments: schistosome genomes and
SCORE
In mid-2009, the research community has witnessed
the fruition of another scientiﬁc milestone, as the
current special issue to Parasitology is preceded by
the publication of the 363 megabase nuclear genome
of S. mansoni in Nature (Berriman et al. 2009),
alongside the draft genomic sequence of S. japoni-
cum (The Schistosoma japonicum Genome Sequenc-
ing and Functional Analysis Consortium, 2009).
An important motivation to analyse the molecular
architecture of these two blood ﬂukes was the
pressing need to discover and develop new anti-
schistosomal drug targets. Indeed, the treatment and
control of schistosomiasis virtually relies on a single
tool, praziquantel (Caﬀrey, 2007; Danso-Appiah
et al. 2009; Doenhoﬀ, Cioli and Utzinger, 2008;
Doenhoﬀ et al. 2009). While the two Nature articles
provide major new insights into the biology and
evolution of S. mansoni and S. japonicum, and
identify a host of parasite proteins that might be
harnessed to discover new antischistosomal drug
lead candidates, they also highlight diﬀerences be-
tween the genomes of these two schistosome species.
It has been noted elsewhere that there is currently
insuﬃcient genome and transcriptome information
for the third major schistosome species, S. haema-
tobium (Rollinson, 2009). Moreover, there is a pau-
city of in vitro and in vivo research pertaining to
S. haematobium, which is a major hindering factor
for focused discovery and development research to
ﬁll the antischistosomal drug pipeline (Doenhoﬀ
et al. 2009).
Last but not least, with new insight gained at a
molecular level, a host of operational research ques-
tions remain and new ones arise, particularly in view
of growing emphasis on preventive chemotherapy
targeting multiple neglected tropical diseases sim-
ultaneously. Among other issues, the optimal timing
of praziquantel administration needs further reﬁne-
ment and a detailed understanding of transmission
dynamics is key (Augusto et al. 2009). Moreover, the
most suitable and locally-accepted delivery strat-
egies for large-scale administration of anthelminthic
drugs (e.g. school-based or community-based ap-
proach) need to be evaluated, including issues of
coverage, cost-eﬀectiveness and sustainability (Massa
et al. 2009). Some of these operational research
questions will be addressed through the Schisto-
somiasis Consortium for Operational Research and
Evaluation (SCORE), funded by the Bill and
Melinda Gates Foundation.
A PREFACE TO THIS SPECIAL ISSUE
OF PARASITOLOGY
Bringing together the current overview, an editorial
by WHO and 17 original research articles and re-
views, has seen the co-operation, help and support
from not less than 75 contributing authors, mainly
from Africa and Europe (Fig. 2). Seven of these
papers feature an African as ﬁrst author, which
represents a much more equitable authorship con-
ﬁguration than what is usually seen in the core
tropical medicine literature (Keiser et al. 2004).
Balancing both basic and operational research, as
well as highlighting progress and pit-falls of schisto-
somiasis control in sub-Saharan Africa has been a
formidable challenge. However, the truly inter-
national partnership in operation here, with many of
the contributing authors working in formal research
partnerships based within institutions that bridge
North and South areas of the world, served as the
platform to facilitate this endeavour. Most import-
antly the authors represent not only experts in their
particular ﬁeld but also key advocates and propo-
nents of ongoing neglected tropical disease control
programmes. For example, many are working at the
coal-face of national interventions in sub-Saharan
Africa and by sharing their advice and experiences
is, we believe, an important future testimony for
decades to come.
In producing this special issue, wemust ﬁrst ﬁrmly
acknowledge Dr. Les Chappell, the co-ordinating
editor, who has been able to guide us all through this
highly evolved, electronic world of scientiﬁc pub-
lishing. Indeed, Les’s eﬀorts have been herculean
in keeping up to date with all the numerous e-mails
passing through his oﬃce and we are especially
grateful to Cambridge University Press for their gen-
erous support in bringing this project to fruition.
A particularly prophetic comment made by
Jordan and Webbe in their 1969 monograph, which
holds true today was ‘‘It is likely that the provision of
adequate funds and properly trained personnel will only
result from the adoption of control programmes at a
national level with the possible assistance of inter-
national agencies ’’ and sets a theme throughout this
special issue. It is thus implicit that countries
should, with appropriate external support where
necessary, best grow their own national plans largely
by themselves to scale-up activities and take signiﬁ-
cant steps to better implement and harmonise all
intervention activities. Indeed, Human Schistoso-
miasis is generally acknowledged to have had a pro-
found impact upon the public health interventions of
today, but few could have predicted that morbidity
control through large-scale administration of anthel-
minthic drugs – a strategy now termed ‘preventive
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chemotherapy’ – would increasingly take centre
stage to become the mainstay and arguably the most
pragmatic public health intervention of today’s
measures against schistosomiasis and other neg-
lected tropical diseases (WHO, 2006; Hotez et al.
2007). Such a change has created new opportunities
for control which seemingly outshine those based
upon improving sanitation and better water hygiene
alone, which were then given greater favour. How-
ever, the fundamental role of economic develop-
ment, which will foster improved access to clean
water and adequate sanitation cannot be over-
emphasised and will ultimately lead to sustainable
control of schistosomiasis and a host of other
helminthic, bacterial and viral diseases.
From the new opportunities, a number of oppor-
tune questions arise, most importantly: ‘‘What is the
exact and lasting endurance of such recent initiatives? ’’
This special issue has been structured in ﬁve sections
in a way to group papers reﬂecting several most
pertinent issues. Following the WHO editorial em-
phasising the development and further evolution of
WHA Resolution 54.19 (Savioli et al. 2009), a ﬁrst
section of three papers follows that discuss issues
of implementing control interventions at diﬀerent
spatial scales (Brooker et al. 2009; Simoonga et al.
2009; Vounatsou et al. 2009). With the often patchy,
focal distribution of schistosomiasis and other neg-
lected tropical diseases, there are new challenges
for rapid identiﬁcation of disease risk not only using
space satellite-based technologies but also in
‘ground-truthing’ these data for estimation of actual
numbers to be treated through time. Creation of
useful spatially-explicit databases that enable disease
control managers and stakeholders to make informed
decisions is becoming ever more crucial to enhance
the cost-eﬀectiveness of control. In addition, feeding
this information accurately to international agencies
is also vital to ensure that the global supply chain of
medications does not become choked.
The second section with another three papers
highlights and reviews the considerable progress
that has been made in the control of schistosomiasis
and soil-transmitted helminthiasis at the national
level, with or without SCI support (Fenwick et al.
2009; Garba et al. 2009; Tchuem Tchuente´ and
N’Goran, 2009). It appears that intersectoral
co-operation and collaboration is essential, yet not
always easy to achieve. A signiﬁcant future challenge
will be to develop and sustain the necessary cadre of
staﬀ to be able to implement each intervention in an
equitable and harmonised way.
Immediate areas of programmatic optimisation
are identiﬁed in the third section consisting of four
papers (Aagaard-Hansen et al. 2009; Augusto et al.
2009; Fleming et al. 2009; Massa et al. 2009). For
example, ways are fostered to encourage better
compliance and timing of praziquantel treatment
Africa
(n=31.5)
Europe
(n=40.5)
Australia
(n=2)
USA
(n=1)
Uganda (n=7)
United Republic of 
Tanzania (n=6)
Mali (n=5)
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Fig. 2. Geographical analysis according to author aﬃliations of the 75 contributing authors to this special issue
of Parasitology. Please note that if an author is aﬃliated to two diﬀerent countries, each country is counted only half,
which explains that the Netherlands and Kenya reached only 0.5.
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within the recipient community. Since monitoring
and evaluation of any intervention are essential steps
within any large-scale programme, the papers in the
fourth section emphasise the interaction between
research and control from the molecular to the
population level (Rollinson et al. 2009; Stothard
et al. 2009; Webster et al. 2009). In particular, at-
tention is drawn to dynamics of disease morbidity
indicators as well as schistosome and intermediate
host snail population dynamics. In the ﬁfth and ﬁnal
section, the unique properties of praziquantel are
stressed (safety, eﬃcacy and low cost) and the
tremendous role this antischistosomal drug has
played for morbidity control of schistosomiasis
around the world is highlighted (Doenhoﬀ et al.
2008; Danso-Appiah et al. 2009; Sacko et al. 2009;
Utzinger et al. 2009). The pressing need for devel-
opment of novel antischistosomal drugs and the
strengthening of health systems that will serve as the
platforms to facilitate integrated control of neglected
tropical disease in the future are discussed.
CONCLUDING REMARKS
It should be recognised that for an enduring impact
against schistosomiasis and other helminthic dis-
eases the vista for control should be seen from a
perspective of several decades of sustained inter-
vention, and not in years as often dictated by the
donor-agencies. One must also remember that in
areas where permissive snail intermediate hosts
commonly occur, levels of environmental trans-
mission might be slow to dampen even with eﬀective
chemotherapy. With this suite of 18 papers the
present and future history of control of schisto-
somiasis in sub-Saharan Africa is far from complete
as the story is yet unfolding and much more could be
achieved with better molluscan control. In Africa
nothing is ever certain, and at the national level, the
political stability in certain sub-Saharan countries is
a very relative concept which, in turn, determines
whether sustainable interventions stand or fall. From
another outlook, the international ﬁnancial funding-
base necessary to sustain the present set of national
control programmes, through donated funds and
drugs, has not yet stabilised and is still only a small
fraction of what is actually needed. With the recent
global economic down-turn further erosion of re-
sources for control will likely increase as ﬁnancial
uncertainties, especially that of governments as well
as donor-agencies themselves, grow.
Bringing together and ﬁrmly securing all the
necessary ingredients to ensure programmatic sus-
tainability for continuous control of schistosomiasis
in sub-Saharan Africa is sadly not yet within reach.
However, the increasing advocacy and massive
scale-up of large-scale drug-based control pro-
grammes have already resulted in signiﬁcant re-
ductions of morbidity due to lymphatic ﬁlariasis,
onchocerciasis and soil-transmitted helminthiasis,
which bodes well for morbidity control of schisto-
somiasis. This will be felt especially where equitable
partnerships between agencies are formed and where
interventions can be more and more integrated into
the existing health system rather than creating par-
allel vertical structures alongside it. It is our hope
that when the ﬁrst human will set foot on planet
Mars, the control of schistosomiasis in sub-Saharan
Africa will have shifted from morbidity control to
transmission control, or even local elimination, and
at the same time leave behind aquatic environments
rich in biological diversity, for generations to come.
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